Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jan;72(1):83-8.
doi: 10.1136/annrheumdis-2012-201697. Epub 2012 Sep 12.

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

Carrie L Wagner  1 , Sudha Visvanathan, Michael Elashoff, Iain B McInnes, Philip J Mease, Gerald G Krueger, Frederick T Murphy, Kim Papp, Juan J Gomez-Reino, Michael Mack, Anna Beutler, Dafna Gladman, Arthur Kavanaugh
Affiliations
Free PMC article
Randomized Controlled Trial

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

Carrie L Wagner et al. Ann Rheum Dis. 2013 Jan.
Free PMC article

Abstract

Objective: To determine serum biomarker associations with clinical response to golimumab treatment in patients with psoriatic arthritis (PsA).

Methods: GO-REVEAL was a randomised, placebo-controlled study of golimumab in patients with active PsA. Samples were collected from 100 patients at baseline, week 4 and week 14, and analysed for serum-based biomarkers and protein profiling (total 92 markers); data were correlated with clinical measures at week 14.

Results: Serum levels of a subset of proteins (apolipoprotein C III, ENRAGE, IL-16, myeloperoxidase, vascular endothelial growth factor, pyridinoline, matrix metalloproteinase 3, C-reactive protein (CRP), carcinoembryonic antigen, intercellular adhesion molecule 1 and macrophage inflammatory protein 1α) at baseline or week 4 were strongly associated with American College of Rheumatology 20% improvement (ACR20) response and/or disease activity score in 28 joints (DAS28) at week 14. A smaller subset of proteins was significantly associated with a 75% improvement in the psoriasis area and severity index score (PASI75) at week 14, (adiponectin, apolipoprotein CIII, serum glutamic oxaloacetic transaminase, and tumour necrosis factor α). Subsets of proteins were identified as potentially predictive of clinical response for each of the clinical measures, and the power of these biomarker panels to predict clinical response to golimumab treatment was stronger than for CRP alone.

Conclusions: This analysis provides insight into several panels of markers that may have utility in identifying PsA patients likely to have ACR20, DAS28, or PASI75 responses following golimumab treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Heat map profile of serum markers in which the changes at week 4 or 14 were significantly different in patients treated with golimumab versus placebo. IL, interleukin; ICAM, intercellular adhesion molecule; MCP, monocyte chemotactic protein-1; MDC, macrophage-derived chemokine; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; PAI-1; plasminogen activator inhibitor 1; VEGF, vascular endothelial growth factor.
See this image and copyright information in PMC

References

    1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis; epidemiology, clinical features, course, and outcomes. Ann Rheum Dis 2005;64(Suppl. 2):ii14–17 - PMC - PubMed
    1. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003;14:241–9 - PubMed
    1. van Kuijk AW, Reinders-Blankert P, Smeets TJ, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006;65:1551–7 - PMC - PubMed
    1. van Kuijk AW, Wijbrandts CA, Vinkenoog M, et al. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann Rheum Dis 2010;69:301–4 - PMC - PubMed
    1. Xia L, Shen H, Xiao W, et al. Increased serum TWEAK levels in Psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels. Cytokine 2011;53:289–91 - PubMed

Publication types